Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

go back to reference Arrieta, O., Guzmán-de Alba, E., Alba-López, L.F., Acosta-Espinoza, A., Alatorre-Alexander, J., Alexander-Meza, J.F., Allende-Pérez, S.R., Alvarado-Aguilar, S., Araujo-Navarrete, M.E., Argote-Greene, L.M., Aquino-Mendoza, C.A., Astorga-Ramos, A.M., Astudillo-de la Vega, A., Avilés-Salas, A., Barajas-Figueroa, L.J., Barroso-Quiroga, N., Blake-Cerda, M., Cabrera-Galeana, P.A., Calderillo-Ruíz, G., Campos-Parra, A.D., et al.: Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev. Invest. Cli. 65(Suppl 1), S5–S84 (2013) Arrieta, O., Guzmán-de Alba, E., Alba-López, L.F., Acosta-Espinoza, A., Alatorre-Alexander, J., Alexander-Meza, J.F., Allende-Pérez, S.R., Alvarado-Aguilar, S., Araujo-Navarrete, M.E., Argote-Greene, L.M., Aquino-Mendoza, C.A., Astorga-Ramos, A.M., Astudillo-de la Vega, A., Avilés-Salas, A., Barajas-Figueroa, L.J., Barroso-Quiroga, N., Blake-Cerda, M., Cabrera-Galeana, P.A., Calderillo-Ruíz, G., Campos-Parra, A.D., et al.: Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev. Invest. Cli. 65(Suppl 1), S5–S84 (2013)

go back to reference Geografía, I.N.d.E.y. http://www.inegi.org.mx/ (2014). Accessed 5 May 2014 Geografía, I.N.d.E.y. http://​www.​inegi.​org.​mx/​ (2014). Accessed 5 May 2014

go back to reference Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D.: Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011). doi:10.3322/caac.20107 CrossRefPubMed Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D.: Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011). doi:10.​3322/​caac.​20107 CrossRefPubMed

go back to reference Society, A.C.: Cancer facts & figures 2013. In: Society, A.C. (ed.). Atlanta (2013) Society, A.C.: Cancer facts & figures 2013. In: Society, A.C. (ed.). Atlanta (2013)

go back to reference Arrieta, O., Martinez-Barrera, L., Trevino, S., Guzman, E., Castillo-Gonzalez, P., Rios-Trejo, M.A., Flores-Estrada, D., Tellez, E., Gonzalez, C., de la Cruz Vargas, J., Gonzalez-De la Rosa, C.H., Hernandez-Pedro, N., Morales-Barrera, R., De la Garza, J.: Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 3(8), 887–893 (2008). doi:10.1097/JTO.0b013e31818026f6 Arrieta, O., Martinez-Barrera, L., Trevino, S., Guzman, E., Castillo-Gonzalez, P., Rios-Trejo, M.A., Flores-Estrada, D., Tellez, E., Gonzalez, C., de la Cruz Vargas, J., Gonzalez-De la Rosa, C.H., Hernandez-Pedro, N., Morales-Barrera, R., De la Garza, J.: Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 3(8), 887–893 (2008). doi:10.​1097/​JTO.​0b013e31818026f6​

go back to reference Delbaldo, C., Michiels, S., Syz, N., Soria, J.C., Le Chevalier, T., Pignon, J.P.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292(4), 470–484 (2004). doi:10.1001/jama.292.4.470 CrossRefPubMed Delbaldo, C., Michiels, S., Syz, N., Soria, J.C., Le Chevalier, T., Pignon, J.P.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292(4), 470–484 (2004). doi:10.​1001/​jama.​292.​4.​470 CrossRefPubMed

go back to reference Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P., Baselga, J.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 21(12), 2237–2246 (2003). doi:10.1200/JCO.2003.10.038 CrossRef Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P., Baselga, J.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 21(12), 2237–2246 (2003). doi:10.​1200/​JCO.​2003.​10.​038 CrossRef

go back to reference Spiro, S.G., Silvestri, G.A.: The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med. 11(4), 287–291 (2005)CrossRefPubMed Spiro, S.G., Silvestri, G.A.: The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med. 11(4), 287–291 (2005)CrossRefPubMed

go back to reference Group NMAC: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 26(28), 4617–4625 (2008). doi:10.1200/JCO.2008.17.7162 CrossRef Group NMAC: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 26(28), 4617–4625 (2008). doi:10.​1200/​JCO.​2008.​17.​7162 CrossRef

go back to reference Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr, T.J., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J., Kay, A.C.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003). doi:10.1001/jama.290.16.2149 CrossRefPubMed Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr, T.J., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J., Kay, A.C.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003). doi:10.​1001/​jama.​290.​16.​2149 CrossRefPubMed

go back to reference Shiroiwa, T., M.Y., Tsutani, K. : Cost-effectiveness analysis of EGFR testing and gefitinib for non small-cell lung cancer (NSCLC) in Japan. Paper presented at the 17th annual international meeting of the International Society for Pharmaeconomics and Outcomes Research (ISPOR), Washington, USA, 2–6 June 2012 Shiroiwa, T., M.Y., Tsutani, K. : Cost-effectiveness analysis of EGFR testing and gefitinib for non small-cell lung cancer (NSCLC) in Japan. Paper presented at the 17th annual international meeting of the International Society for Pharmaeconomics and Outcomes Research (ISPOR), Washington, USA, 2–6 June 2012

go back to reference Shepherd, F.A., Pereira, J.R., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P., Seymour, L., National Cancer Institute of Canada Clinical Trials G: Erlotinib in previously treated non-small-cell lung cancer. New Engl. J. Med. 353(2), 123–132 (2005). doi:10.1056/NEJMoa050753 CrossRefPubMed Shepherd, F.A., Pereira, J.R., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P., Seymour, L., National Cancer Institute of Canada Clinical Trials G: Erlotinib in previously treated non-small-cell lung cancer. New Engl. J. Med. 353(2), 123–132 (2005). doi:10.​1056/​NEJMoa050753 CrossRefPubMed

go back to reference Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E.H., Pemberton, K., Archer, V., Carroll, K.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527–1537 (2005). doi:10.1016/S0140-6736(05)67625-8 CrossRefPubMed Thatcher, N., Chang, A., Parikh, P., Pereira, J.R., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E.H., Pemberton, K., Archer, V., Carroll, K.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527–1537 (2005). doi:10.​1016/​S0140-6736(05)67625-8 CrossRefPubMed

go back to reference Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350(21), 2129–2139 (2004). doi:10.1056/NEJMoa040938 CrossRefPubMed Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350(21), 2129–2139 (2004). doi:10.​1056/​NEJMoa040938 CrossRefPubMed

go back to reference Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004). doi:10.1126/science.1099314 CrossRefPubMed Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004). doi:10.​1126/​science.​1099314 CrossRefPubMed

go back to reference Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M.: Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 361(10), 947–957 (2009). doi:10.1056/NEJMoa0810699 CrossRefPubMed Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A., Fukuoka, M.: Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 361(10), 947–957 (2009). doi:10.​1056/​NEJMoa0810699 CrossRefPubMed

go back to reference Park, K., Goto, K.: A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr. Med. Res. Opin. 22(3), 561–573 (2006). doi:10.1185/030079906X89847 CrossRefPubMed Park, K., Goto, K.: A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr. Med. Res. Opin. 22(3), 561–573 (2006). doi:10.​1185/​030079906X89847 CrossRefPubMed

go back to reference Han, J.Y., Park, K., Kim, S.W., Lee, D.H., Kim, H.Y., Kim, H.T., Ahn, M.J., Yun, T., Ahn, J.S., Suh, C., Lee, J.S., Yoon, S.J., Han, J.H., Lee, J.W., Jo, S.J., Lee, J.S.: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 30(10), 1122–1128 (2012). doi:10.1200/JCO.2011.36.8456 CrossRef Han, J.Y., Park, K., Kim, S.W., Lee, D.H., Kim, H.Y., Kim, H.T., Ahn, M.J., Yun, T., Ahn, J.S., Suh, C., Lee, J.S., Yoon, S.J., Han, J.H., Lee, J.W., Jo, S.J., Lee, J.S.: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 30(10), 1122–1128 (2012). doi:10.​1200/​JCO.​2011.​36.​8456 CrossRef

go back to reference Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., North-East Japan Study G: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 362(25), 2380–2388 (2010). doi:10.1056/NEJMoa0909530 CrossRefPubMed Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., North-East Japan Study G: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl. J. Med. 362(25), 2380–2388 (2010). doi:10.​1056/​NEJMoa0909530 CrossRefPubMed

go back to reference Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M., West Japan Oncology G: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010). doi:10.1016/S1470-2045(09)70364-X CrossRefPubMed Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., Fukuoka, M., West Japan Oncology G: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010). doi:10.​1016/​S1470-2045(09)70364-X CrossRefPubMed

go back to reference Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). doi:10.1016/S1470-2045(11)70184-X CrossRefPubMed Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). doi:10.​1016/​S1470-2045(11)70184-X CrossRefPubMed

go back to reference Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L., Spanish Lung Cancer Group in collaboration with Groupe Francais de, P.-C, Associazione Italiana Oncologia T: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). doi:10.1016/S1470-2045(11)70393-X CrossRefPubMed Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L., Spanish Lung Cancer Group in collaboration with Groupe Francais de, P.-C, Associazione Italiana Oncologia T: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). doi:10.​1016/​S1470-2045(11)70393-X CrossRefPubMed

go back to reference Sequist, L.V., Yang, J.C., Yamamoto, N., O’Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., Su, W.C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K.H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 31(27), 3327–3334 (2013). doi:10.1200/JCO.2012.44.2806 CrossRef Sequist, L.V., Yang, J.C., Yamamoto, N., O’Byrne, K., Hirsh, V., Mok, T., Geater, S.L., Orlov, S., Tsai, C.M., Boyer, M., Su, W.C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K.H., Shah, R., Massey, D., Zazulina, V., Shahidi, M., Schuler, M.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J.Clin. Oncol. Off. J Am. Soc. Clin. Oncol. 31(27), 3327–3334 (2013). doi:10.​1200/​JCO.​2012.​44.​2806 CrossRef

go back to reference Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J.H., Lee, K.Y., Xu, C.R., Massey, D., Kim, M., Shi, Y., Geater, S.L.: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014). doi:10.1016/S1470-2045(13)70604-1 CrossRefPubMed Wu, Y.L., Zhou, C., Hu, C.P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J.H., Lee, K.Y., Xu, C.R., Massey, D., Kim, M., Shi, Y., Geater, S.L.: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014). doi:10.​1016/​S1470-2045(13)70604-1 CrossRefPubMed

go back to reference Arrieta, O., Cardona, A.F., Bramuglia, G.F., Gallo, A., Campos-Parra, A.D., Serrano, S., Castro, M., Aviles, A., Amorin, E., Kirchuk, R., Cuello, M., Borbolla, J., Riemersma, O., Becerra, H., Rosell, R., ClicaP: Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6(11), 1955–1959 (2011). doi:10.1097/JTO.0b013e31822f655f Arrieta, O., Cardona, A.F., Bramuglia, G.F., Gallo, A., Campos-Parra, A.D., Serrano, S., Castro, M., Aviles, A., Amorin, E., Kirchuk, R., Cuello, M., Borbolla, J., Riemersma, O., Becerra, H., Rosell, R., ClicaP: Genotyping non-small cell lung cancer (NSCLC) in Latin America. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 6(11), 1955–1959 (2011). doi:10.​1097/​JTO.​0b013e31822f655f​

go back to reference Arrieta, O., Cardona, A.F., Martin, C., Mas-Lopez, L., Corrales-Rodriguez, L., Bramuglia, G., Castillo-Fernandez, O., Meyerson, M., Amieva-Rivera, E., Campos-Parra, A.D., Carranza, H., de Gomez la Torre, J.C., Powazniak, Y., Aldaco-Sarvide, F., Vargas, C., Trigo, M., Magallanes-Maciel, M., Otero, J., Sanchez-Reyes, R., Cuello, M.: Updated frequency of EGFR and KRAS mutations in non-small-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). thorac. oncol. off. publ. Int. Assoc. Study Lung Cancer 10(5), 838–843 (2015). doi:10.1097/JTO.0000000000000481 Arrieta, O., Cardona, A.F., Martin, C., Mas-Lopez, L., Corrales-Rodriguez, L., Bramuglia, G., Castillo-Fernandez, O., Meyerson, M., Amieva-Rivera, E., Campos-Parra, A.D., Carranza, H., de Gomez la Torre, J.C., Powazniak, Y., Aldaco-Sarvide, F., Vargas, C., Trigo, M., Magallanes-Maciel, M., Otero, J., Sanchez-Reyes, R., Cuello, M.: Updated frequency of EGFR and KRAS mutations in non-small-cell lung cancer in Latin America: the Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). thorac. oncol. off. publ. Int. Assoc. Study Lung Cancer 10(5), 838–843 (2015). doi:10.​1097/​JTO.​0000000000000481​

go back to reference Arrieta, O., Nunez-Valencia, C., Reynoso-Erazo, L., Alvarado, S., Flores-Estrada, D., Angulo, L.P., Onate-Ocana, L.F.: Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1), 205–211 (2012). doi:10.1016/j.lungcan.2012.02.005 CrossRefPubMed Arrieta, O., Nunez-Valencia, C., Reynoso-Erazo, L., Alvarado, S., Flores-Estrada, D., Angulo, L.P., Onate-Ocana, L.F.: Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1), 205–211 (2012). doi:10.​1016/​j.​lungcan.​2012.​02.​005 CrossRefPubMed

go back to reference Campos-Parra, A.D., Zuloaga, C., Manriquez, M.E., Aviles, A., Borbolla-Escoboza, J., Cardona, A., Meneses, A., Arrieta, O.: KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am. J. Clin. Oncol. 38(1), 33–40 (2015). doi:10.1097/COC.0b013e318287bb23 CrossRefPubMed Campos-Parra, A.D., Zuloaga, C., Manriquez, M.E., Aviles, A., Borbolla-Escoboza, J., Cardona, A., Meneses, A., Arrieta, O.: KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am. J. Clin. Oncol. 38(1), 33–40 (2015). doi:10.​1097/​COC.​0b013e318287bb23​ CrossRefPubMed

go back to reference Arrieta, O., Cardona, A.F., Corrales, L., Campos-Parra, A.D., Sanchez-Reyes, R., Amieva-Rivera, E., Rodriguez, J., Vargas, C., Carranza, H., Otero, J., Karachaliou, N., Astudillo, H., Rosell, R., ClicaP: The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer 87(2), 169–175 (2015). doi:10.1016/j.lungcan.2014.12.009 CrossRefPubMed Arrieta, O., Cardona, A.F., Corrales, L., Campos-Parra, A.D., Sanchez-Reyes, R., Amieva-Rivera, E., Rodriguez, J., Vargas, C., Carranza, H., Otero, J., Karachaliou, N., Astudillo, H., Rosell, R., ClicaP: The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer 87(2), 169–175 (2015). doi:10.​1016/​j.​lungcan.​2014.​12.​009 CrossRefPubMed

go back to reference Heon, S., Yeap, B.Y., Lindeman, N.I., Joshi, V.A., Butaney, M., Britt, G.J., Costa, D.B., Rabin, M.S., Jackman, D.M., Johnson, B.E.: The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18(16), 4406–4414 (2012). doi:10.1158/1078-0432.CCR-12-0357 CrossRef Heon, S., Yeap, B.Y., Lindeman, N.I., Joshi, V.A., Butaney, M., Britt, G.J., Costa, D.B., Rabin, M.S., Jackman, D.M., Johnson, B.E.: The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18(16), 4406–4414 (2012). doi:10.​1158/​1078-0432.​CCR-12-0357 CrossRef

go back to reference Arrieta, O., Campos-Parra, A.D., Zuloaga, C., Aviles, A., Sanchez-Reyes, R., Manriquez, M.E., Covian-Molina, E., Martinez-Barrera, L., Meneses, A., Cardona, A., Borbolla-Escoboza, J.R.: Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 7(8), 1228–1234 (2012). doi:10.1097/JTO.0b013e3182582a93 Arrieta, O., Campos-Parra, A.D., Zuloaga, C., Aviles, A., Sanchez-Reyes, R., Manriquez, M.E., Covian-Molina, E., Martinez-Barrera, L., Meneses, A., Cardona, A., Borbolla-Escoboza, J.R.: Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 7(8), 1228–1234 (2012). doi:10.​1097/​JTO.​0b013e3182582a93​

go back to reference Chen, W., E.P., Levin, L., et al.: Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario. Paper presented at the 16th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, USA, 21–25 May Chen, W., E.P., Levin, L., et al.: Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario. Paper presented at the 16th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, USA, 21–25 May

go back to reference Jacob, J., H.M., Brattstrbm, D. : Cost-effectiveness of gefitinib versus doublet chemotherapy in first-line treatment of non-small cell lung cancer (NSCLC) in Sweden. Paper presented at 13th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic., 6–9 Nov Jacob, J., H.M., Brattstrbm, D. : Cost-effectiveness of gefitinib versus doublet chemotherapy in first-line treatment of non-small cell lung cancer (NSCLC) in Sweden. Paper presented at 13th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic., 6–9 Nov

go back to reference de Lima Lopes Jr, G., Segel, J.E., Tan, D.S., Do, Y.K., Mok, T., Finkelstein, E.A.: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012). doi:10.1002/cncr.26372 CrossRefPubMed de Lima Lopes Jr, G., Segel, J.E., Tan, D.S., Do, Y.K., Mok, T., Finkelstein, E.A.: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118(4), 1032–1039 (2012). doi:10.​1002/​cncr.​26372 CrossRefPubMed

go back to reference Arrieta, O., Quintana-Carrillo, R.H., Ahumada-Curiel, G., Corona-Cruz, J.F., Correa-Acevedo, E., Zinser-Sierra, J., de la Mata-Moya, D., Mohar-Betancourt, A., Morales-Oyarvide, V., Reynales-Shigematsu, L.M.: Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the national cancer institute of Mexico. Tob. Induc. Dis. 12(1), 25 (2014). doi:10.1186/s12971-014-0025-4 CrossRefPubMed Arrieta, O., Quintana-Carrillo, R.H., Ahumada-Curiel, G., Corona-Cruz, J.F., Correa-Acevedo, E., Zinser-Sierra, J., de la Mata-Moya, D., Mohar-Betancourt, A., Morales-Oyarvide, V., Reynales-Shigematsu, L.M.: Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the national cancer institute of Mexico. Tob. Induc. Dis. 12(1), 25 (2014). doi:10.​1186/​s12971-014-0025-4 CrossRefPubMed

go back to reference Kohler, J., Schuler, M.: Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9), 510–518 (2013). doi:10.1159/000354627 CrossRefPubMed Kohler, J., Schuler, M.: Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9), 510–518 (2013). doi:10.​1159/​000354627 CrossRefPubMed

go back to reference Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Osterlind, K., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652), 1809–1818 (2008). doi:10.1016/S0140-6736(08)61758-4 CrossRefPubMed Kim, E.S., Hirsh, V., Mok, T., Socinski, M.A., Gervais, R., Wu, Y.L., Li, L.Y., Watkins, C.L., Sellers, M.V., Lowe, E.S., Sun, Y., Liao, M.L., Osterlind, K., Reck, M., Armour, A.A., Shepherd, F.A., Lippman, S.M., Douillard, J.Y.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652), 1809–1818 (2008). doi:10.​1016/​S0140-6736(08)61758-4 CrossRefPubMed

go back to reference Westwood, M., Joore, M., Whiting, P., van Asselt, T., Ramaekers, B., Armstrong, N., Misso, K., Severens, J., Kleijnen, J.: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 18(32), 1–166 (2014). doi:10.3310/hta18320 CrossRef Westwood, M., Joore, M., Whiting, P., van Asselt, T., Ramaekers, B., Armstrong, N., Misso, K., Severens, J., Kleijnen, J.: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 18(32), 1–166 (2014). doi:10.​3310/​hta18320 CrossRef

go back to reference Health Quality O: Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 10(24), 1–48 (2010) Health Quality O: Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer: an evidence-based analysis. Ont. Health Technol. Assess. Ser. 10(24), 1–48 (2010)

go back to reference Handorf, E.A., McElligott, S., Vachani, A., Langer, C.J., Bristol Demeter, M., Armstrong, K., Asch, D.A.: Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J. Oncol. Pract. Am. Soc. Clin. Oncol. 8(5), 267–274 (2012). doi:10.1200/JOP.2011.000502 CrossRef Handorf, E.A., McElligott, S., Vachani, A., Langer, C.J., Bristol Demeter, M., Armstrong, K., Asch, D.A.: Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. J. Oncol. Pract. Am. Soc. Clin. Oncol. 8(5), 267–274 (2012). doi:10.​1200/​JOP.​2011.​000502 CrossRef

go back to reference Romanus, D., Cardarella, S., Cutler, D., Landrum, M.B., Lindeman, N.I., Gazelle, G.S.: Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 10(4), 586–594 (2015). doi:10.1097/JTO.0000000000000474 Romanus, D., Cardarella, S., Cutler, D., Landrum, M.B., Lindeman, N.I., Gazelle, G.S.: Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 10(4), 586–594 (2015). doi:10.​1097/​JTO.​0000000000000474​

go back to reference Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013). doi:10.1371/journal.pone.0055917 CrossRefPubMedPubMedCentral Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013). doi:10.​1371/​journal.​pone.​0055917 CrossRefPubMedPubMedCentral

go back to reference Carlson, J.J., Garrison, L.P., Ramsey, S.D., Veenstra, D.L.: Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 135(11), 1483–1493 (2009). doi:10.1007/s00432-009-0595-3 CrossRefPubMed Carlson, J.J., Garrison, L.P., Ramsey, S.D., Veenstra, D.L.: Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 135(11), 1483–1493 (2009). doi:10.​1007/​s00432-009-0595-3 CrossRefPubMed

go back to reference Graham, D.M., Leighl, N.B.: Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine. Front. oncol. 4, 258 (2014). doi:10.3389/fonc.2014.00258 CrossRefPubMedPubMedCentral Graham, D.M., Leighl, N.B.: Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine. Front. oncol. 4, 258 (2014). doi:10.​3389/​fonc.​2014.​00258 CrossRefPubMedPubMedCentral

go back to reference Hayes, D.N., Kim, W.Y.: The next steps in next-gen sequencing of cancer genomes. J. Clin. Investig. 125(2), 462–468 (2015). doi:10.1172/JCI68339 CrossRefPubMedPubMedCentral Hayes, D.N., Kim, W.Y.: The next steps in next-gen sequencing of cancer genomes. J. Clin. Investig. 125(2), 462–468 (2015). doi:10.​1172/​JCI68339 CrossRefPubMedPubMedCentral

go back to reference Dawe, D.E., Ellis, P.M.: Challenges in implementing personalized medicine for lung cancer within a national healthcare system. J. Personal. Med. 2(3), 77–92 (2012). doi:10.3390/jpm2030077 CrossRef Dawe, D.E., Ellis, P.M.: Challenges in implementing personalized medicine for lung cancer within a national healthcare system. J. Personal. Med. 2(3), 77–92 (2012). doi:10.​3390/​jpm2030077 CrossRef

go back to reference Carlos-Rivera, F., J, R.-G., Aguirre-Granados, A.: Cost of adverse events of bevacizumab plus interferon-alfa2a compared with sunitinib for first-line treatment of metastatic renal cell carcinoma. Gaceta Mexicana de Oncol. 9(6), 255–265 (2010) Carlos-Rivera, F., J, R.-G., Aguirre-Granados, A.: Cost of adverse events of bevacizumab plus interferon-alfa2a compared with sunitinib for first-line treatment of metastatic renal cell carcinoma. Gaceta Mexicana de Oncol. 9(6), 255–265 (2010)